350 FIFTH AVENUE, NEW YORK, NY
Market cap: $350.6M (2/10/2026)
Price: $3.24
Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Changes in Board, Management or Compensation
Other Events
News, Material Contracts
FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
Q3
Q2
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Effectiveness Notice
Certificate
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement